Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...

Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the ...

Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

Taiba also has a right to negotiate a licence to develop and commercialise DMX-200 in any additional indications in the licensed territories that Dimerix may achieve for DMX-200. The minimum term for ...

Dr Nina Webster is the CEO and managing director of Dimerix (ASX:DXB), which in mid-CY25 is due to report the second interim results of its ACTION3 global phase III trial of lead drug DMX-200 to treat ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.

Highlights,Recruitment begins for the first paediatric patient in a pivotal kidney disease trial.,19 specialist sites across multiple countries involved in the paediatric study plan.,Interim data ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Opyl enters joint venture with X Firm to market its AI-powered TrialKey platform in Europe, Middle ...